Robert W. Simms

2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative

F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen et al. · Arthritis & Rheumatism · 2013 · 3.3K citations · Full text

2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative

F.H.J. van den Hoogen, Dinesh Khanna, Jaap Fransen et al. · Annals of the Rheumatic Diseases · 2013 · 2.8K citations

Cyclophosphamide versus Placebo in Scleroderma Lung Disease

Donald P. Tashkin, Robert M. Elashoff, Philip J. Clements et al. · New England Journal of Medicine · 2006 · 1.6K citations · Full text

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial

Donald P. Tashkin, Michael D. Roth, Philip J. Clements et al. · The Lancet Respiratory Medicine · 2016 · 1K citations · Full text

Sls Ii, Mycophenolate Mofetil, Inflammatory Lung Disease +9

Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist

J H Korn, Maureen D. Mayes, M Matucci Cerinic et al. · Arthritis & Rheumatism · 2004 · 720 citations